NFG
CRSP icon

Norris Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Norris Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$494K Buy
9,061
+1,804
+25% +$95.1K 0.2% 50
2026
Q1 		$345K Sell
7,257
-585
-7% -$30.9K 0.11% 70
2025
Q4 		$411K Sell
7,842
-112
-1% -$6.71K 0.14% 70
2025
Q3 		$515K Sell
7,954
-1,771
-18% -$102K 0.19% 62
2025
Q2 		$473K Buy
9,725
+48
+0.5% +$1.86K 0.19% 61
2025
Q1 		$329K Buy
9,677
+3,113
+47% +$132K 0.15% 67
2024
Q4 		$258K Sell
6,564
-3,790
-37% -$179K 0.12% 74
2024
Q3 		$486K Buy
10,354
+240
+2% +$12.2K 0.24% 52
2024
Q2 		$546K Sell
10,114
-2,445
-19% -$141K 0.28% 51
2024
Q1 		$856K Sell
12,559
-2,308
-16% -$165K 0.47% 45
2023
Q4 		$931K Buy
14,867
+417
+3% +$23.1K 0.57% 38
2023
Q3 		$656K Buy
14,450
+2,356
+19% +$122K 0.45% 44
2023
Q2 		$679K Buy
+12,094
New +$686K 0.47% 44
2022
Q2 		– Sell
-3,502
Closed -$220K – 70
2022
Q1 		$220K Buy
+3,502
New +$220K 0.13% 74

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Norris Financial Group's CRSP Position: Q2 2026 in Review

Norris Financial Group increased its CRISPR Therapeutics (CRSP) stake by 25% in Q2 2026, buying an estimated $95.1K and bringing the position to 9,061 shares worth $494K. The position accounts for 0.2% of the portfolio, ranked #50.

Norris Financial Group first reported a position in CRSP in Q1 2022 and has held it in 14 quarters since. The position peaked at $931K in Q4 2023. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Norris Financial Group held 9,061 shares of CRISPR Therapeutics worth $494K as of Q2 2026.
  • Norris Financial Group bought 1,804 CRISPR Therapeutics shares in Q2 2026, an estimated $95.1K.
  • CRISPR Therapeutics made up 0.2% of Norris Financial Group's portfolio in Q2 2026, its #50 holding.
  • Norris Financial Group first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • Norris Financial Group's CRISPR Therapeutics position peaked at $931K in Q4 2023.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Norris Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.